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The pyrimidine nucleoside phosphorylases (PyNP), uridine (UP;
EC 2.4.2.3) and thymidine (TP; EC 2.4.2.4) phosphorylase, are
involved in the salvage pathway of pyrimidine nucleosides, but
also in the activation of fluoropyrimidines. They are responsible
for the conversion of the pro-drug 5¢-deoxy-5-fluorouridine 
(5¢-DFUR, doxifluridine) to its active form 5-fluorouracil (5-FU)
(Armstrong and Diasio, 1980). Because of their reversible phos-
phorolytic activity, UP and TP also assume the conversion of 5-FU
to its anabolites, respectively 5-fluorouridine (5-FUrd) and 5-
fluoro-2¢-deoxyuridine (5-FdUrd) (Ishitsuka et al, 1980; Peters 
et al, 1986). 
PyNP gene transfer into cancer cells in order to increase the meta-
bolic activation of fluoropyrimidines and thus the sensitivity of
transfected cells to these anti-metabolites could be a new strategy in
cancer gene therapy. Encouraging data have been obtained with TP
gene transfer (Patterson et al, 1995; Schwartz et al, 1995; Kato et al,
1997; Evrard et al, 1999a, 1999b). Unlike TP, the data concerning
UP are not numerous. NIH-3T3-derived cells expressing high levels
of UP are more sensitive to fluoropyrimidines than parental cells
(Watanabe et al, 1995). The increase of 5¢DFUR antitumor activity
by an extract from calf thymus (thymosin fraction 5) was attributed
to an increase of UP activity (Ikemoto et al, 1999). In this paper, we
studied the effects of UP overexpression by gene transfer in human
breast cancer cells on the metabolic activation and on the cytotoxi-
city of fluoropyrimidines. 
MATERIALS AND METHODS 
Chemicals 
5-FU, 5¢-DFUR, enhanced chemoluminescence (ECL) and high-
performance liquid chromatography (HPLC) reagents were from
Sigma (St Quentin Fallavier, France). [3H]5-FU (12.5 Ci mmol–1)
was from Du Pont de Nemours (Les Ulis, France). 
Cell lines 
MCF-7 human breast adenocarcinoma cells (ATCC number HTB-
22) were cultured at 37˚C in a fully humidified 5% CO2 atmos-
phere in RPMI 1640 medium supplemented with 10% fetal calf
serum (FCS) and 2 mM glutamine. COS-7 cells (ATCC number
CRL-1651) were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 5% FCS and 2 mM glutamine. 
UP overexpression in COS-7 and MCF-7 cells 
The pUP-SG5 plasmid, containing the full length human UP
cDNA (Watanabe and Uchida, 1995), was kindly provided by 
Dr SH Watanabe (Nippon Roche Research Center, Japan). The
labelling of UP cDNA by a short myc sequence was performed by
PCR using pUP-SG5, pFU polymerase (Stratagene, Amsterdam,
The Netherlands) and specific primers. The myc/UP cDNA was
ligated into the mammalian expression vector pcDNA3
(Invitrogen, NV Leek, The Netherlands) to produce pcmyc/UP.
Cells were transfected with pcmyc/UP, pUP-SG5 or pcDNA3
(control) using Lipofectamine™ (Life Technologies, Cergy-
Pontoise, France). COS-7 cells were lysed after 48 h incubation.
Stable MCF-7 transfectants were selected for 250 mg ml–1
geneticin (Life Technologies, Cergy-Pontoise, France) resistance. 
Immunoblotting 
Proteins from cell lysates were electrophoresed on SDS-polyacl-
amide gel, electroblotted onto nitrocellulose membrane, labelled
with an anti-myc antibody (Invitrogen, France) and visualized
using X-ray films after incubation with ECL reagents as previ-
ously described (Evrard et al, 1999b). 
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The UP activity was assayed as previously described (Watanabe
and Uchida, 1995), with minor modifications. Cell lysates were
incubated for 1 h at 37˚C in the presence of 10 mM uridine and the
uracil, produced by uridine phosphorolysis, was quantified by
HPLC as follows: C18 reverse phase column, 5 mm; mobile phase,
K2 HPO4, 10 mM pH 4; flow rate, 0.5 ml min–1; UV detection. The
UP activity was expressed as nmol uracil mg protein–1 min–1. 
[3H]5-FU metabolism analysis 
After 4 h incubation in the presence of [3H]5-FU (100 mCi), the
tritiated metabolites in cell lysates were, as previously described
(Ciccolini et al, 2000), separated by HPLC coupled to a radio-
metric detector (Flo-One Beta Radiomatic, Packard Instrument
SA). Peaks were identified by comparing retention times with
standards. 
In vitro cytotoxicity assay 
The effects of antimetabolites on cell viability were assessed as
previously described by using the neutral red assay (Evrard et al,
1996). The effect of the drugs on cell survival was expressed as
percentage of viability of treated-cells compared with control
cells. 
RESULTS 
Overexpression of UP in MCF-7 cells 
No endogenous UP activity was detected in parental MCF-7
cells, as well as in pcDNA3-transfected cells (Figure 1). MCF-7
cells were transfected with the pcmyc/UP plasmid which encoded
a functional and immunodetectable myc-tagged UP, as assessed by
transfection into COS-7 cells (Figure 1). Stable transfectants were
selected for geneticin resistance. 3 clones (c1, c7 and c13)
expressing different levels of UP were selected. 
[3H]5-FU metabolism 
Parental and clone 13 MCF-7 cells were incubated in the presence
of [3H]5-FU and the resulting metabolites were identified by
HPLC coupled to a radiometric detection (Figure 2). [3H]-
fluorodeoxyuridine-monophosphate (FdUMP), and tritiated com-
pounds of the RNA pathway (FUrd, FUMP, FUDP and FUTP)
accumulated in parental MCF-7 cells. In MCF-7-c13 cells, the
levels of the FUrd, FUDP and FUTP were strongly increased
(about 89-, 5- and 38-fold, respectively). 
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Figure 1 UP expression and activity in COS-7 and MCF-7 cells. Upper
panel: UP activity in lysates from parental (wt), pcDNA3-(negative control),
pUP-SG5-(positive control), or pcmyc/UP-transfected COS-7 cells, and from
parental (wt), pcDNA3-or pcmyc/UP-transfected MCF-7 cell clones (c1, c7
and c13). The uracil, resulting from uridine phosphorolysis by cell extracts,
was quantified by HPLC. Data are means ± SEM of 3 separate experiments.
Lower panel: proteins from COS-7 and MCF-7 cell lysates were
electrophoresed by SDS-PAGE, blotted onto nitrocellulose sheets and
labelled with an anti-myc antibody 
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Figure 2 Metabolism of [3H]5-FU in MCF-7 cells. Parental or clone 13 MCF-7
cells were incubated for 4 hours in the presence of 100 mCi [3H]5-FU 
(1.6 mM) and the resulting tritiated metabolites were identified by HPLC coupled
to a radiometric detection. Data are from one representative experiment 
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Figure 3 Effect of UP expression on the in vitro sensitivity of MCF-7 cells to
5-FU and 5¢DFUR. Parental (open circles) MCF-7-c7 (closed circles) or MCF-
7-c13 (closed triangles) were incubated for 72 h at 37˚C in the presence of
increasing concentrations (0.1 to 1000 mM) of 5-FU (A) and 5¢DFUR (B). Cell
viability was studied by using the neutral red uptake assay. Data, expressed
as percentage of viability of treated cells compared with control cells, are
means ± SEM of 4 separate experiments In vitro cytotoxicity 
5-FU and 5¢-DFUR decreased the viability of parental cells, as
well as that of pcmyc/UP-transfected cells (c7 and c13), in a
concentration-dependent fashion (Figure 3). The fluoropyrimidine
sensitivity of the myc/UP-overexpressing MCF-7 clones was not
significantly (Student’s t-test) different from that of parental cells,
or from that of pcDNA3-transfected cells (data not shown). 
DISCUSSION 
The metabolic activation of fluoropyrimidines can be initiated by
UP and/or TP. Correlations between TP expression level and, on
one hand the in vitro fluoropyrimidine cytotoxicity (Schwartz 
et al, 1995; Evrard et al, 1999a, 1999b), on the other hand the
clinical outcome of fluoropyrimidine-based therapy (Koizumi
et al, 1999; Saito et al, 1999) have been established. Thus, TP was
proposed as a potential suicide gene for cancer gene therapy with
5¢DFUR (Haraguchi et al, 1993; Patterson et al, 1995; Kanyama
et al, 1999) or with 5-FU (Evrard et al, 1999a, 1999b). On the
contrary, there was no clear demonstration of the importance of UP
expression in tumours for fluoropyrimidine cytotoxicity. To
address this question, UP was expressed by gene transfer in MCF-
7 breast cancer cells. These cells were chosen because breast
cancer is a major indication for 5-FU based therapy. Moreover, it
was previously shown that MCF-7 cells do not express UP mRNA
(Watanabe and Uchida, 1995); as expected, we did not detect any
UP activity in parental cells. 
HPLC experiments were performed to compare the [3H]5-FU
metabolic activation profiles in parental and MCF-7-c13 cells
which exhibited the highest UP level. Parental cells displayed an
accumulation of [3H]FdUMP, reflecting the activation of [3H]5-FU
by the DNA pathway, but also of low amounts of 5-FU anabolites
of the RNA pathway (FUrd, FUMP, FUDP and FUTP). These data
were in agreement with previous reports (Kufe and Major, 1981;
Peter et al, 1986; Patterson et al, 1995; Ackland and Peters, 1999)
showing that MCF-7 cells can activate 5-FU through both RNA
(initiated by TP) and DNA (initiated by FU conversion to FUMP
by orotate phosphoribosyl transferase) pathways. When UP-
expressing MCF-7-c13 cells were incubated in the presence of
[3H]5-FU, high levels of [3H]FUrd and [3H]fluororibonucleotides
(FUDP, FUTP) were detected. This metabolic activation profile
clearly indicates that human UP efficiently increases the metabolic
activation of 5-FU through the RNA pathway when it is expressed
in MCF-7 cells. 
The effects of UP expression on the in vitro sensitivity of MCF-
7 cells to antimetabolites were then studied. We found that MCF-
7-c13 cells are not more sensitive to fluoropyrimidines than
parental or pcDNA3-transfected cells. Thus, UP overexpression
does not increase the 5-FU sensitivity of MCF-7 cells, even if the
drug is effeciently metabolized. As reported by Patterson et al
(1995), it seems likely that the DNA pathway is the most efficient
activation pathway of fluoropyrimidines in MCF-7 cells. We
previously obtained similar results (Evrard et al, 1999b) with
LS174T colon cancer cells: despite an efficient metabolic activa-
tion of 5-FU by UP through the RNA pathway, parental LS174T
cells were less sensitive to fluoropyrimidines than TP-transfected
cells. Taken together, these data indicate that UP is not as impor-
tant as TP for an efficient metabolic activation of fluoropyrim-
idines leading to a high cytotoxic effect. 
In conclusion, this study shows that the UP activity level is not
related to the sensitivity to 5-FU and 5¢-DFUR of human MCF-7
breast cancer cells. Our data should provide rationale, on one hand
for measuring TP rather than UP in clinical material in order to
correlate with outcome of fluoropyrimidine based therapy, on the
other hand for considering TP rather than UP as a potential suicide
gene for cancer gene therapy with 5-FU or 5¢DFUR. 
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